CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 164 enrolled
Drug / intervention
Ivermectin +3 moredrug
Likely dose
Ivermectin 200 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04410406
NCT04410406Phase 3Completed
CompareCT.gov

A Clinical Trial to Assess the Safety and Efficacy of Moxidectin Combination Treatments vs. Ivermectin Combination Treatments for Bancroftian Filariasis

Washington University School of Medicine·interventional·Posted Jun 1, 2020·Updated Jan 29, 2026

In Brief

A Phase 3 clinical trial evaluating Ivermectin, Diethylcarbamazine, and 2 other interventions for Lymphatic Filariasis. Completed, enrolled 164 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether moxidectin (Mox) will be more effective than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis (LF).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphatic Filariasis
CountriesCôte d’Ivoire
CollaboratorsCase Western Reserve University, Centre Suisse de Recherches Scientifiques en Cote d'Ivoire

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedJun 1, 2020
Enrollment StartAug 20, 2020
Primary CompletionOct 1, 2024
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 6.1 years ago

Interventions

Ivermectindrug

Ivermectin (IVM) 200 µg/kg

Diethylcarbamazinedrug

Diethylcarbamazine (DEC) 6mg/kg

Albendazoledrug

Albendazole (ABZ) 400 mg

Moxidectindrug

Moxidectin (Mox) 8 mg